Cervical Cancer

Molecular docking confirmed the stable binding of compound 1 to B-cell lymphoma 2 (BCL-2) and mitogen-activated protein kinase kinase 1 (MAP2K1) with binding free energies of -8.9 kcal mol-1 and -9.6 kcal mol-1, respectively. Overall, these results elucidate the dual antitumor mechanisms of compound 1, demonstrating its potential as a lead candidate for treating leukaemia and cervical cancer.

P=N/A, N=901, Recruiting, University of Illinois at Chicago | Trial completion date: May 2027 --> Aug 2027 | Trial primary completion date: May 2026 --> Mar 2027

P2, N=50, Not yet recruiting, Fred Hutchinson Cancer Center

Moreover, we demonstrated that circPTP4A2 enhances the expression of EEF2, a downstream target of miR-183-5p. Collectively, our findings elucidate that circPTP4A2 promotes NSCLC progression by sponging miR-183-5p to upregulate EEF2, suggesting it could be a promising therapeutic target for NSCLC.

P2, N=200, Not yet recruiting, Lisa Flowers | Trial completion date: Oct 2027 --> Oct 2028 | Trial primary completion date: Oct 2027 --> Oct 2028

P=N/A, N=750, Not yet recruiting, University of California, San Diego

P=N/A, N=200, Not yet recruiting, Rutgers, The State University of New Jersey

Trend analysis demonstrated significant monotonic increases for both markers across disease stages (P<0.001). This study provides a standardized, stage-specific immunohistochemical evaluation of CPE and ALDH1A1 in cervical lesions, highlighting progressive CPE upregulation and invasion-associated ALDH1A1 expression, and adds methodological clarity to the existing literature.

In patients with cervical cancer, BRCA testing holds important clinical value, particularly for the management of those with a significant family history of malignancy or confirmed hereditary predisposition. Appropriate genetic counseling plays an essential role in guiding preventive strategies, facilitating early diagnosis, and supporting informed decision-making regarding potential prophylactic interventions.

These data suggest that TSPAN8 drives EMT-mediated radioresistance in cervical cancer, is associated with recurrence and poor survival, and represents a potential biomarker and therapeutic target. Targeting TSPAN8 may enhance radiosensitivity and improve personalized radiotherapy outcomes.

P=N/A, N=120, Not yet recruiting, University of South Dakota

Mirvetuximab soravtansine (MIRV), which targets folate receptor-1 (FOLR1), is FDA-approved for platinum-resistant tubo-ovarian cancers with ≥75% moderate/strong staining, and emerging studies show meaningful responses to MIRV combination therapy even at lower FOLR1 expression. FOLR1 met current MIRV treatment criteria in one case, while ten others showed expression ranging from 5% to 70%. Although most tumors did not meet current biomarker thresholds for Trastuzumab or MIRV monotherapy, detectable expression supports exploring anti-HER2 T-Dxd and MIRV combination treatments in selected MA/MLA cases.